vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Williams-Sonoma, Inc. (WSM). Click either name above to swap in a different company.

Williams-Sonoma, Inc. is the larger business by last-quarter revenue ($1.9B vs $994.2M, roughly 1.9× Charles River Laboratories). Williams-Sonoma, Inc. runs the higher net margin — 12.8% vs -27.8%, a 40.6% gap on every dollar of revenue. On growth, Williams-Sonoma, Inc. posted the faster year-over-year revenue change (4.6% vs -0.8%). Williams-Sonoma, Inc. produced more free cash flow last quarter ($248.1M vs $58.6M). Over the past eight quarters, Charles River Laboratories's revenue compounded faster (-0.9% CAGR vs -9.1%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Williams Sonoma is an American retailer of cookware, appliances, and home furnishings. It is owned by Williams-Sonoma, Inc., and was founded by Charles E. (Chuck) Williams in 1956.

CRL vs WSM — Head-to-Head

Bigger by revenue
WSM
WSM
1.9× larger
WSM
$1.9B
$994.2M
CRL
Growing faster (revenue YoY)
WSM
WSM
+5.4% gap
WSM
4.6%
-0.8%
CRL
Higher net margin
WSM
WSM
40.6% more per $
WSM
12.8%
-27.8%
CRL
More free cash flow
WSM
WSM
$189.5M more FCF
WSM
$248.1M
$58.6M
CRL
Faster 2-yr revenue CAGR
CRL
CRL
Annualised
CRL
-0.9%
-9.1%
WSM

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CRL
CRL
WSM
WSM
Revenue
$994.2M
$1.9B
Net Profit
$-276.6M
$241.6M
Gross Margin
46.1%
Operating Margin
-28.5%
17.0%
Net Margin
-27.8%
12.8%
Revenue YoY
-0.8%
4.6%
Net Profit YoY
-28.9%
-3.0%
EPS (diluted)
$-5.57
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
WSM
WSM
Q4 25
$994.2M
$1.9B
Q3 25
$1.0B
$1.8B
Q2 25
$1.0B
$1.7B
Q1 25
$984.2M
$2.5B
Q4 24
$1.0B
$1.8B
Q3 24
$1.0B
$1.8B
Q2 24
$1.0B
$1.7B
Q1 24
$1.0B
$2.3B
Net Profit
CRL
CRL
WSM
WSM
Q4 25
$-276.6M
$241.6M
Q3 25
$54.4M
$247.6M
Q2 25
$52.3M
$231.3M
Q1 25
$25.5M
$384.9M
Q4 24
$-214.5M
$249.0M
Q3 24
$69.7M
$225.7M
Q2 24
$94.1M
$265.7M
Q1 24
$73.0M
$354.4M
Gross Margin
CRL
CRL
WSM
WSM
Q4 25
46.1%
Q3 25
47.1%
Q2 25
44.3%
Q1 25
45.2%
Q4 24
46.7%
Q3 24
34.6%
46.2%
Q2 24
34.5%
48.3%
Q1 24
34.1%
46.0%
Operating Margin
CRL
CRL
WSM
WSM
Q4 25
-28.5%
17.0%
Q3 25
13.3%
17.9%
Q2 25
9.7%
16.8%
Q1 25
7.6%
20.1%
Q4 24
-16.7%
17.8%
Q3 24
11.6%
16.2%
Q2 24
14.8%
19.5%
Q1 24
12.5%
20.1%
Net Margin
CRL
CRL
WSM
WSM
Q4 25
-27.8%
12.8%
Q3 25
5.4%
13.5%
Q2 25
5.1%
13.4%
Q1 25
2.6%
15.6%
Q4 24
-21.4%
13.8%
Q3 24
6.9%
12.6%
Q2 24
9.2%
16.0%
Q1 24
7.2%
15.6%
EPS (diluted)
CRL
CRL
WSM
WSM
Q4 25
$-5.57
$1.96
Q3 25
$1.10
$2.00
Q2 25
$1.06
$1.85
Q1 25
$0.50
$1.02
Q4 24
$-4.17
$1.96
Q3 24
$1.33
$1.74
Q2 24
$1.74
$4.07
Q1 24
$1.30
$5.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
WSM
WSM
Cash + ST InvestmentsLiquidity on hand
$213.8M
$884.7M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$3.2B
$2.1B
Total Assets
$7.1B
$5.3B
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
WSM
WSM
Q4 25
$213.8M
$884.7M
Q3 25
$207.1M
$985.8M
Q2 25
$182.8M
$1.0B
Q1 25
$229.4M
$1.2B
Q4 24
$194.6M
$826.8M
Q3 24
$210.2M
$1.3B
Q2 24
$179.2M
$1.3B
Q1 24
$327.0M
$1.3B
Total Debt
CRL
CRL
WSM
WSM
Q4 25
$2.1B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.5B
Q4 24
$2.2B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.7B
Stockholders' Equity
CRL
CRL
WSM
WSM
Q4 25
$3.2B
$2.1B
Q3 25
$3.4B
$2.1B
Q2 25
$3.4B
$2.2B
Q1 25
$3.2B
$2.1B
Q4 24
$3.5B
$1.9B
Q3 24
$3.8B
$2.3B
Q2 24
$3.7B
$2.2B
Q1 24
$3.6B
$2.1B
Total Assets
CRL
CRL
WSM
WSM
Q4 25
$7.1B
$5.3B
Q3 25
$7.5B
$5.2B
Q2 25
$7.6B
$5.2B
Q1 25
$7.6B
$5.3B
Q4 24
$7.5B
$5.0B
Q3 24
$8.0B
$5.2B
Q2 24
$7.9B
$5.2B
Q1 24
$8.2B
$5.3B
Debt / Equity
CRL
CRL
WSM
WSM
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
WSM
WSM
Operating Cash FlowLast quarter
$147.5M
$316.3M
Free Cash FlowOCF − Capex
$58.6M
$248.1M
FCF MarginFCF / Revenue
5.9%
13.2%
Capex IntensityCapex / Revenue
8.9%
3.6%
Cash ConversionOCF / Net Profit
1.31×
TTM Free Cash FlowTrailing 4 quarters
$518.5M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
WSM
WSM
Q4 25
$147.5M
$316.3M
Q3 25
$213.8M
$282.7M
Q2 25
$204.6M
$118.9M
Q1 25
$171.7M
$633.5M
Q4 24
$159.4M
$253.5M
Q3 24
$251.8M
$246.5M
Q2 24
$193.5M
$226.8M
Q1 24
$129.9M
$674.9M
Free Cash Flow
CRL
CRL
WSM
WSM
Q4 25
$58.6M
$248.1M
Q3 25
$178.2M
$230.7M
Q2 25
$169.3M
$60.7M
Q1 25
$112.4M
$566.3M
Q4 24
$83.7M
$170.1M
Q3 24
$213.1M
$215.1M
Q2 24
$154.0M
$187.3M
Q1 24
$50.7M
$621.2M
FCF Margin
CRL
CRL
WSM
WSM
Q4 25
5.9%
13.2%
Q3 25
17.7%
12.6%
Q2 25
16.4%
3.5%
Q1 25
11.4%
23.0%
Q4 24
8.4%
9.4%
Q3 24
21.1%
12.0%
Q2 24
15.0%
11.3%
Q1 24
5.0%
27.3%
Capex Intensity
CRL
CRL
WSM
WSM
Q4 25
8.9%
3.6%
Q3 25
3.5%
2.8%
Q2 25
3.4%
3.4%
Q1 25
6.0%
2.7%
Q4 24
7.5%
4.6%
Q3 24
3.8%
1.8%
Q2 24
3.8%
2.4%
Q1 24
7.8%
2.4%
Cash Conversion
CRL
CRL
WSM
WSM
Q4 25
1.31×
Q3 25
3.93×
1.14×
Q2 25
3.91×
0.51×
Q1 25
6.74×
1.65×
Q4 24
1.02×
Q3 24
3.61×
1.09×
Q2 24
2.06×
0.85×
Q1 24
1.78×
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

WSM
WSM

Segment breakdown not available.

Related Comparisons